News and Updates

The ADA’s Scientific Sessions is completed! Here, with the post-day recap, is Marlon Pragnell, Ph.D., head of the complications program at Breakthrough T1D, with a recap of type 1 diabetes complications research and results from the ADA conference:

The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immune therapy program at Breakthrough T1D, who highlights some of the important immune-based therapies and what they mean for the type 1 diabetes community:

There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here is Jessica Dunne, Ph.D., senior director of the prevention portfolio, who gives a recap of day in T1D prevention research:

We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from Breakthrough T1D‘s assistant director for science, Andy Rakeman, Ph.D.:

The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement therapies. Happy viewing!

The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world. Breakthrough T1D researchers and Breakthrough T1D-funded scientists will also be there to hear first-hand and present new study results […]

Breakthrough T1D International is deeply saddened at the loss of one of Breakthrough T1D Canada’s co-founders, Helaine Shiff. “Helaine was a remarkable woman and her legacy to our community will live on forever,” said Dave Prowten, President and CEO of Breakthrough T1D Canada. “She never let up and continued to the very end to help […]

In a second win for the type 1 diabetes (T1D) community, the European Commission has approved Zynquista™ (sotagliflozin) for use in adults with T1D with a body mass index (BMI) above or equal to 27 kg/m2, in combination with insulin to improve blood-sugar control. It and Forxiga® (dapagliflozin and marketed in the United States as […]

Chief Mission Officer to assume leadership baton from Derek Rapp After a thorough national search, the Breakthrough T1D International Board of Directors has unanimously voted on and approved the appointment of Aaron J. Kowalski, Ph.D., to serve as its new President and CEO, leading Breakthrough T1D’s race to cure type 1 diabetes and to improve […]

More than 120 Young Adults joined Breakthrough T1D for a weekend of networking, learning and connecting at the Breakthrough T1D Young Adult Conference held in Dallas, Texas on March 30 and 31. Find the photos of this electrifying conference here. The conference experience was enriched by speakers who inspired our participants by talking about living […]